Screen Shot 2019-02-26 at 6.11.44 PM.png


Stroke is one of Australia’s biggest killers and a leading cause of disability. In 2017 there were more than 56,000 new and recurrent strokes – that is one stroke every nine minutes. The financial cost of stroke in Australia is estimated to be $5 billion each year.

The Stroke Foundation’s comprehensive Clinical Guidelines for Stroke Management are evolving into living guidelines as a next generation solution for health evidence translation in stroke..

This three-year pilot project will build and evaluate a world-first, online, dynamically updating summary of stroke evidence to guide clinical practice and policy development. The project is a partnership between the Stroke Foundation and Cochrane Australia, and is supported by the Australian government’s Medical Research Future Fund.

For more information please contact 



Diabetes is an National Health Priority area that affects approx. 1.7 million Australians and represents an estimated $15 billion per annum in direct and indirect costs to the Australian economy.

As part of the implementation plan for the Australian National Diabetes Strategy 2016-2020, several key diabetes organisations are partnering to establish two living evidence demonstration projects in areas that reflect a high priority for decision making in diabetes management, and where there is uncertainty in the existing evidence and a high likelihood of emerging evidence:

  1. Recommendations for which therapies are best for blood glucose control in type 2 diabetes?

  2. Recommendations for the use of technology for managing diabetes (eg pumps, continuous glucose monitoring, flash glucose monitoring).

The LG4D project is a partnership between Australian Diabetes Society, Diabetes Australia, Australian Diabetes Educators Association, Australasian Paediatric Endocrine Group and Cochrane Australia and is supported by the Australian government Department of Health.

For more information about this frontier project please contact Heath White,

Screen Shot 2019-02-26 at 6.16.53 PM.png
Screen Shot 2019-02-26 at 6.11.44 PM.png


Arthritis and musculoskeletal (MSK) conditions like back pain affect more than 6 million Australians and are the fourth leading contributor to Australia’s total burden of illness.

As part of a comprehensive program of MSK research funded under the NHMRC Centres of Research Excellence scheme, the Australian and New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC) is working to establish living systematic reviews of treatments for common MSK conditions.

This includes a living review and network meta-analysis of all available drugs for rheumatoid arthritis. The project aims to provide a living dataset that is open for use by guideline developers to support living evidence-based guideline recommendations.

For more information about this frontier project please contact Dr Sam Whittle,



Kidney diseases affect one in eight Australian adults and can lead to early death and disability. Over 200,000 Australians have kidney disease and most are unaware. Kidney disease is estimated to cost Australia $1 billion each year in health costs alone.

For people with kidney disease, the risk of dying from a cardiovascular event such as a heart attack or stroke is 20 times higher than the risk of requiring dialysis or a kidney transplant.

Early detection and effective treatment to lower blood pressure and cholesterol can substantially reduce risks of heart disease. Unfortunately many opportunities for these treatments are not taken – fewer than half of patients with kidney disease receive adequate blood pressure therapy.

The Kidney Health Australia – CARI guidelines for cardiovascular management are being transformed into a living process for delivering evidence to the clinic to support greater use of effective therapies.

This 18-month project will bring partners including Kidney Health Australia, Cochrane, consumers living with kidney disease and clinicians together to develop a rapid and trustworthy method to update the cardiovascular guidelines for kidney health.

The project is supported by the Australia and New Zealand Society of Nephrology, BEAT-CKD, and Kidney Health Australia.

 For more information, please contact

Screen Shot 2019-02-26 at 6.16.53 PM.png
Screen Shot 2019-02-26 at 6.11.44 PM.png


Heart disease is Australia’s leading single cause of death. Heart disease also has a significant impact on the economy – for example, ischaemic heart disease costs Australia around $7.3b per year. There were 18,590 Australian lives lost to heart disease in 2017.

The Heart Foundation is a major funder and developer of clinical practice guidelines and decision aids for the prevention, screening, diagnosis, and management of heart disease (including acute coronary syndromes, atrial fibrillation, heart failure, hypertension, and absolute cardiovascular risk).

The Heart Foundation joined the Australian Living Evidence Consortium in January 2019 to develop a pilot living guideline project and is currently undertaking scoping and prioritisation to identify suitable topic areas.

For more information please contact Cia Connell,


If you’d like to discuss developing a Living Evidence project or explore other opportunities for collaborating with us, please get in touch–we’d love to hear from you.

Back to top

Screen Shot 2019-02-26 at 6.16.53 PM.png